EpimAb Biotherapeutics Inc. Files HKEX Listing Application for the Third Time, Core Asset EMB-01 Enters Phase II Clinical Trials
NewTimeSpace News: EpimAb Biotherapeutics Inc. submitted its third Main Board listing application to the Hong Kong Stock Exchange on 24 June, with CICC and China Merchants Bank International acting as joint sponsors. Founded in 2015, the Company is a clinical-stage biotechnology enterprise dedicated to developing bispecific antibody therapeutics for various cancers and autoimmune diseases. Its core product EMB-01 (targeting EGFR/cMET) is currently under Phase II development as a third-line monotherapy.
NewTimeSpace News: As disclosed by the Hong Kong Stock Exchange, EpimAb Biotherapeutics Inc. filed its third Main Board listing application with HKEX on 24 June 2026, jointly sponsored by CICC and China Merchants Bank International.
Founded in 2015, EpimAb Biotherapeutics is a clinical-stage biotech firm focusing on the research and development of bispecific antibody therapies for diverse malignancies and autoimmune disorders. Its self-developed pipeline covers four clinical-stage drug candidates and four preclinical assets.
The flagship asset EMB-01, an EGFR/cMET-targeted bispecific antibody primarily indicated for metastatic colorectal cancer, is being advanced in two clinical phases: Phase II development as third-line monotherapy and Phase Ib development for combination treatment regimens.
In addition, EMB-06 (targeting BCMA/CD3) is being developed for relapsed/refractory multiple myeloma and autoimmune diseases, while EMB-07 and EMB-15 are also in clinical-stage development.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Netjoy (02131.HK): Profit Warning Update, Expected Annual Net Loss Widens to RMB440 Million – RMB480 Million
- Mininglamp Technology (2718.HK) Invited to the Inaugural Beijing-Birmingham Technology Week to Accelerate Overseas Market Expansion
- BRIGHT SMART(01428.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 670.25 million, YoY increase of 8.52%
- LAI GROUP(08455.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 9.46 million, loss narrowed by 27.21% YoY
- EXPERT SYS(08319.HK): FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 3.85 million, YoY decrease of 72.41%
